Open access
Oct 2026
Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer
This economic evaluation assesses the health economic value, for a US Medicare payer, of adopting perioperative enfortumab vedotin plus pembrolizumab for treatment of cisplatin-ineligible patients with muscle-invasive bladder cancer.
Z. Su, Tyler S. Garman, Carlos A. Rivera López et al.
· JAMA Network Open · 0 citations